Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline.
This report aims to provide a comprehensive presentation of the global market for Glioblastoma Multiforme (GBM) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glioblastoma Multiforme (GBM) Therapeutics. This report contains market size and forecasts of Glioblastoma Multiforme (GBM) Therapeutics in global, including the following market information:
Global Glioblastoma Multiforme (GBM) Therapeutics Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Glioblastoma Multiforme (GBM) Therapeutics market was valued at US$ 564.1 million in 2022 and is projected to reach US$ 990.5 million by 2029, at a CAGR of 8.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America dominated the global market in 2017, accounting for over 35% share in terms of revenue. Europe was anOthers major market for glioblastoma multiforme (GBM) therapeutics in 2017. Technological advancement is a major driver of the market in North America and Europe.
We surveyed the Glioblastoma Multiforme (GBM) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Glioblastoma Multiforme (GBM) Therapeutics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Glioblastoma Multiforme (GBM) Therapeutics Market Segment Percentages, by Type, 2022 (%)
ChemOthersapy
Targeted Drug Therapy
Radiation Therapy
Global Glioblastoma Multiforme (GBM) Therapeutics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Glioblastoma Multiforme (GBM) Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Glioblastoma Multiforme (GBM) Therapeutics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Glioblastoma Multiforme (GBM) Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Glioblastoma Multiforme (GBM) Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Glioblastoma Multiforme (GBM) Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva Pharmaceutical
Emcure Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Glioblastoma Multiforme (GBM) Therapeutics, market overview.
Chapter 2: Global Glioblastoma Multiforme (GBM) Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Glioblastoma Multiforme (GBM) Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Glioblastoma Multiforme (GBM) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Glioblastoma Multiforme (GBM) Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Glioblastoma Multiforme (GBM) Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Glioblastoma Multiforme (GBM) Therapeutics Overall Market Size
2.1 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size: 2022 VS 2030
2.2 Global Glioblastoma Multiforme (GBM) Therapeutics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Glioblastoma Multiforme (GBM) Therapeutics Players in Global Market
3.2 Top Global Glioblastoma Multiforme (GBM) Therapeutics Companies Ranked by Revenue
3.3 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Glioblastoma Multiforme (GBM) Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Glioblastoma Multiforme (GBM) Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Glioblastoma Multiforme (GBM) Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Glioblastoma Multiforme (GBM) Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Glioblastoma Multiforme (GBM) Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Glioblastoma Multiforme (GBM) Therapeutics Market Size Markets, 2022 & 2030
4.1.2 ChemOthersapy
4.1.3 Targeted Drug Therapy
4.1.4 Radiation Therapy
4.2 By Type - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2024-2030
4.2.3 By Type - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2024-2030
5.2.3 By Application - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2022 & 2030
6.2 By Region - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2024-2030
6.2.3 By Region - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2030
6.3.2 US Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.3.3 Canada Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.3.4 Mexico Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2030
6.4.2 Germany Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.4.3 France Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.4.4 U.K. Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.4.5 Italy Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.4.6 Russia Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.4.7 Nordic Countries Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.4.8 Benelux Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2030
6.5.2 China Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.5.3 Japan Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.5.4 South Korea Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.5.5 Southeast Asia Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.5.6 India Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2030
6.6.2 Brazil Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.6.3 Argentina Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2030
6.7.2 Turkey Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.7.3 Israel Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.7.4 Saudi Arabia Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
6.7.5 UAE Glioblastoma Multiforme (GBM) Therapeutics Market Size, 2018-2030
7 Glioblastoma Multiforme (GBM) Therapeutics Companies Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.1.4 Merck Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.2.4 Roche Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 Arbor Pharmaceuticals
7.3.1 Arbor Pharmaceuticals Company Summary
7.3.2 Arbor Pharmaceuticals Business Overview
7.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.3.4 Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Arbor Pharmaceuticals Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.4.4 Pfizer Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 AbbVie
7.5.1 AbbVie Company Summary
7.5.2 AbbVie Business Overview
7.5.3 AbbVie Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.5.4 AbbVie Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.5.5 AbbVie Key News & Latest Developments
7.6 Amgen
7.6.1 Amgen Company Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.6.4 Amgen Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Amgen Key News & Latest Developments
7.7 Bristol-Myers Squibb
7.7.1 Bristol-Myers Squibb Company Summary
7.7.2 Bristol-Myers Squibb Business Overview
7.7.3 Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.7.4 Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.7.5 Bristol-Myers Squibb Key News & Latest Developments
7.8 Sun Pharmaceuticals
7.8.1 Sun Pharmaceuticals Company Summary
7.8.2 Sun Pharmaceuticals Business Overview
7.8.3 Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.8.4 Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.8.5 Sun Pharmaceuticals Key News & Latest Developments
7.9 Teva Pharmaceutical
7.9.1 Teva Pharmaceutical Company Summary
7.9.2 Teva Pharmaceutical Business Overview
7.9.3 Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.9.4 Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.9.5 Teva Pharmaceutical Key News & Latest Developments
7.10 Emcure Pharmaceuticals
7.10.1 Emcure Pharmaceuticals Company Summary
7.10.2 Emcure Pharmaceuticals Business Overview
7.10.3 Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Major Product Offerings
7.10.4 Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global Market (2018-2023)
7.10.5 Emcure Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Glioblastoma Multiforme (GBM) Therapeutics Market Opportunities & Trends in Global Market
Table 2. Glioblastoma Multiforme (GBM) Therapeutics Market Drivers in Global Market
Table 3. Glioblastoma Multiforme (GBM) Therapeutics Market Restraints in Global Market
Table 4. Key Players of Glioblastoma Multiforme (GBM) Therapeutics in Global Market
Table 5. Top Glioblastoma Multiforme (GBM) Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Glioblastoma Multiforme (GBM) Therapeutics Product Type
Table 9. List of Global Tier 1 Glioblastoma Multiforme (GBM) Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Glioblastoma Multiforme (GBM) Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Glioblastoma Multiforme (GBM) Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2024-2030
Table 30. Merck Company Summary
Table 31. Merck Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 32. Merck Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. Merck Key News & Latest Developments
Table 34. Roche Company Summary
Table 35. Roche Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 36. Roche Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Roche Key News & Latest Developments
Table 38. Arbor Pharmaceuticals Company Summary
Table 39. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 40. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. Arbor Pharmaceuticals Key News & Latest Developments
Table 42. Pfizer Company Summary
Table 43. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 44. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Pfizer Key News & Latest Developments
Table 46. AbbVie Company Summary
Table 47. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 48. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. AbbVie Key News & Latest Developments
Table 50. Amgen Company Summary
Table 51. Amgen Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 52. Amgen Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Amgen Key News & Latest Developments
Table 54. Bristol-Myers Squibb Company Summary
Table 55. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 56. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. Bristol-Myers Squibb Key News & Latest Developments
Table 58. Sun Pharmaceuticals Company Summary
Table 59. Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 60. Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 61. Sun Pharmaceuticals Key News & Latest Developments
Table 62. Teva Pharmaceutical Company Summary
Table 63. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 64. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 65. Teva Pharmaceutical Key News & Latest Developments
Table 66. Emcure Pharmaceuticals Company Summary
Table 67. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Product Offerings
Table 68. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 69. Emcure Pharmaceuticals Key News & Latest Developments
List of Figures
Figure 1. Glioblastoma Multiforme (GBM) Therapeutics Segment by Type in 2022
Figure 2. Glioblastoma Multiforme (GBM) Therapeutics Segment by Application in 2022
Figure 3. Global Glioblastoma Multiforme (GBM) Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Glioblastoma Multiforme (GBM) Therapeutics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Glioblastoma Multiforme (GBM) Therapeutics Revenue in 2022
Figure 8. By Type - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 16. US Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 20. Germany Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 21. France Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 28. China Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 32. India Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 34. Brazil Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics Revenue Market Share, 2018-2030
Figure 37. Turkey Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Glioblastoma Multiforme (GBM) Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 41. Merck Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Roche Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pfizer Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. AbbVie Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Amgen Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
